Xgeva
Amgen,USA
$200.00-
SelectSpecification/Number
-
ParameterDetailed information
-
NoticeCustoms clearance instructions
-
Required readingConsumption notice
- Description
- Information
INDICATIONS AND USAGE
Multiple Myeloma and Bone Metastasis from Solid Tumors
Xgeva is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
Giant Cell Tumor of Bone
Xgeva is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Hypercalcemia of Malignancy
Xgeva is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
DOSAGE
Important Administration Instructions
Xgeva is intended for subcutaneous route only and should not be administered intravenously, intramuscularly, or intradermally.
Multiple Myeloma and Bone Metastasis from Solid Tumors
The recommended dose of Xgeva is 120 mg administered as a subcutaneous injection every 4 weeks in the upper arm, upper thigh, or abdomen.
Administer calcium and vitamin D as necessary to treat or prevent hypocalcemia.
Giant Cell Tumor of Bone
The recommended dose of Xgeva is 120 mg administered every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. Administer subcutaneously in the upper arm, upper thigh, or abdomen.
Administer calcium and vitamin D as necessary to treat or prevent hypocalcemia.
Hypercalcemia of Malignancy
The recommended dose of Xgeva is 120 mg administered every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. Administer subcutaneously in the upper arm, upper thigh, or abdomen.
ADVERSE REACTIONS
Hypersensitivity
Hypocalcemia
Osteonecrosis of the Jaw
Atypical Subtrochanteric and Diaphyseal Femoral Fracture
Hypercalcemia following treatment discontinuation in patients with giant cell tumor of bone and in patients with growing skeletons
Multiple vertebral fractures (MVF) following treatment discontinuation
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/628f0998-1206-4001-aeee-18133aa9f3bf/spl-doc?hl=Xgeva
Xgevainformation
No information yet!!!